IVERIC bio, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2020-06-22: Study NCT04435366; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2018-11: Study NCT03374670; Company role Lead sponsor; Phase Phase 2; Status Withdrawn.
- 2017-10-11: Study NCT03362190; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2016-10-20: Study NCT05571267; Company role Lead sponsor; Phase Phase 2; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2020-06-22 | NCT04435366 A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) | Lead sponsor | Phase 3 | Completed Results posted | Geographic Atrophy; Macular Degeneration | 448 | 2023-08-22 |
| 2018-11 | NCT03374670 ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) | Lead sponsor | Phase 2 | Withdrawn | Idiopathic Polypoidal Choroidal Vasculopathy | 0 | 2019-12 |
| 2017-10-11 | NCT03362190 ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) | Lead sponsor | Phase 2 | Completed Results posted | Neovascular Age-related Macular Degeneration | 64 | 2018-10-18 |
| 2016-10-20 | NCT05571267 Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD | Lead sponsor | Phase 2 | Terminated Results posted | Neovascular Age-Related Macular Degeneration | 1 | 2018-04-24 |
| 2016-04-26 | NCT02387957 A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) | Lead sponsor | Phase 2 | Terminated Results posted | Age-Related Macular Degeneration | 63 | 2017-01 |
| 2015-12-15 | NCT02686658 Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | Geographic Atrophy; Dry Age-Related Macular Degeneration | 286 | 2020-04-23 |
| 2015-03-12 | NCT02397954 A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) | Lead sponsor | Phase 2 | Completed Results posted | Idiopathic Polypoidal Choroidal Vasculopathy | 4 | 2015-10-23 |
| 2014-07 | NCT02214628 Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD | Lead sponsor | Phase 2 | Terminated Results posted | Age-related Macular Degeneration | 101 | 2016-12 |
| 2014-05 | NCT01940887 A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy | Lead sponsor | Phase 3 | Terminated Results posted | Age-Related Macular Degeneration | 645 | 2017-09 |
| 2014-02 | NCT02591914 An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration | Collaborator Lead: Retinal Consultants of Arizona | Phase 1 | Completed | Neovascular Age-Related Macular Degeneration | 30 | 2016-05-24 |
| 2013-08 | NCT01944839 A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy | Lead sponsor | Phase 3 | Terminated Results posted | Age-Related Macular Degeneration | 619 | 2016-12 |
| 2013-08 | NCT01940900 A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy | Lead sponsor | Phase 3 | Terminated Results posted | Age-Related Macular Degeneration | 627 | 2016-12 |
| 2010-03 | NCT01089517 A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration | Lead sponsor | Phase 2 | Completed Results posted | Age-Related Macular Degeneration | 449 | 2012-06 |
| 2009-07-16 | NCT00950638 A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration | Lead sponsor | Phase 1 | Completed | Dry Age-Related Macular Degeneration | 47 | 2011-03-24 |
| 2008-10-16 | NCT00709527 ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration | Lead sponsor | Phase 1 | Completed | Neovascular Age-Related Macular Degeneration | 60 | 2009-12-30 |
| 2008-10 | NCT00782093 A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration | Lead sponsor | Phase 1 | Completed | Age-related Macular Degeneration | 63 | 2012-06 |
| 2007-12 | NCT00569140 A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration | Lead sponsor | Phase 1 | Completed | Age-related Macular Degeneration | 18 | 2008-12 |